Team cracks the atomic structure of a major cancer drug target

Jan 19, 2010
The crystal structure of the complex between the VEGF-C growth factor and the VEGFR2 receptor. The VEGF-C polypeptide chains are colored in yellow and green and the receptor chains are colored in light blue. The sugar moieties are in purple.

(PhysOrg.com) -- Researchers at the University of Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand binding domain of a vascular endothelial growth factor (VEGF) receptor in complex with one of its ligands (VEGF-C).

Cancer cells require access to blood and lymph vessels for invasive growth and metastasis. By releasing VEGFs, stimulate the surrounding blood vessels to invade the cancerous tumor mass. Blocking this process is a new strategy to inhibit .

VEGFs and their receptors have been identified as major targets for drug development in and the VEGF receptor that the groups analyzed is currently the most important target of such drugs. The Finnish group discovered the VEGF-C growth factor in 1996 and found that it is involved in lymphatic vessel growth, cancer metastasis and, more recently, also in blood vessel growth in .

The collaborative work published in PNAS by the two research teams provides significant new insights into VEGF receptor function. It was also made possible by the long-standing interest and collaborative research of the binational team and the availability of excellent crystallography beamlines at the Swiss Synchrotron Light Source located at PSI, and supported by the European Union.

Explore further: Prognostic factors identified for peripheral squamous cell carcinomas of the lung

More information: V-M Leppänen, A Prota, M Jeltsch, A Anisimov, N Kalkkinen, T Strandin, H Lankinen, A Goldman, K Ballmer-Hofer and K Alitalo, Structural determinants of growth factor binding and specificity by VEGF-Receptor 2. Proc. Natl. Acad. Sci. USA

Provided by University of Helsinki

4 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

A longer lasting tumor blocker

Apr 28, 2009

On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially better option. ...

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments : 0